Paul A. Friedman
Chief Executive Officer at Madrigal Pharmaceuticals Inc.
Sits on 2 boards. Last updated September 28, 2026
Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Madrigal Pharmaceuticals Inc., 3 years.
Madrigal Pharmaceuticals Inc.
Director · Chief Executive Officer
Prelude Therapeutics Incorporated
Director
Chief executive roles
Madrigal Pharmaceuticals Inc.
· Chief Executive Officer
Until September 2023
· Former
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 25, 2024 | Madrigal Pharmaceuticals Inc. | Grant or award | +714 | — | — |
| Apr 8, 2024 | Madrigal Pharmaceuticals Inc. | Option exercise | +26,270 | $9.45 | $248,252 |
| Apr 8, 2024 | Madrigal Pharmaceuticals Inc. | Open-market sale | −1,441 | $242.95 | $350,091 |
| Apr 8, 2024 | Madrigal Pharmaceuticals Inc. | Open-market sale | −3,730 | $244.12 | $910,568 |
| Apr 8, 2024 | Madrigal Pharmaceuticals Inc. | Open-market sale | −5,663 | $244.86 | $1,386,642 |
| Apr 8, 2024 | Madrigal Pharmaceuticals Inc. | Open-market sale | −2,078 | $245.71 | $510,585 |
| Apr 8, 2024 | Madrigal Pharmaceuticals Inc. | Open-market sale | −5,028 | $246.96 | $1,241,715 |
| Apr 8, 2024 | Madrigal Pharmaceuticals Inc. | Open-market sale | −3,464 | $247.76 | $858,241 |
| Apr 8, 2024 | Madrigal Pharmaceuticals Inc. | Open-market sale | −4,866 | $248.59 | $1,209,639 |
| Apr 5, 2024 | Madrigal Pharmaceuticals Inc. | Option exercise | +27,613 | $9.45 | $260,943 |
| Apr 5, 2024 | Madrigal Pharmaceuticals Inc. | Open-market sale | −1,420 | $240.10 | $340,942 |
| Apr 5, 2024 | Madrigal Pharmaceuticals Inc. | Open-market sale | −612 | $241.15 | $147,584 |
| Apr 5, 2024 | Madrigal Pharmaceuticals Inc. | Open-market sale | −6,679 | $242.42 | $1,619,123 |
| Apr 5, 2024 | Madrigal Pharmaceuticals Inc. | Open-market sale | −9,264 | $243.20 | $2,253,005 |
| Apr 5, 2024 | Madrigal Pharmaceuticals Inc. | Open-market sale | −3,966 | $244.22 | $968,577 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.